Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Status:
Withdrawn
Trial end date:
2019-11-27
Target enrollment:
Participant gender:
Summary
This research study is studying the safety, tolerability, and tumor activity of the study
drug known as rogaratinib as a possible treatment for bladder cancer.